News

Publication of a clinical phase 1 study of SCO-240: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders

Presentation of clinical data of SCO-240 at the 96^th annual congress of Japan Endocrine Society: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders

Presentation of new preclinical data of GLUT5 inhibitor at the Experimental Biology 2021: GLUT5 inhibition is a novel strategy to treat fructose-induced diseases

Conference presentation regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)

Publication regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)

Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease

Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat NAFLD

Publication regarding the compound profiles of SCO-792,a novel enteropeptidase inhibitor

Presentation of New Preclinical Data of SCO-267, a GPR40 agonist, at The American Diabetes Association’s 79th Scientific Sessions

Publication regarding a preclinical study of SCO-267,a novel GPR40 agonist